Gelteq Limited (NASDAQ:GELS – Get Free Report) saw a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 37,312 shares, a decrease of 34.3% from the April 15th total of 56,786 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 12,987 shares, the days-to-cover ratio is presently 2.9 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings cut Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Analysis on Gelteq
Gelteq Stock Performance
Institutional Investors Weigh In On Gelteq
A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP acquired a new position in shares of Gelteq Limited (NASDAQ:GELS – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq at the end of the most recent quarter.
About Gelteq
Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.
Further Reading
- Five stocks we like better than Gelteq
- 3 Infrastructure Stocks Fueling the Data Center Building Boom
- Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
